Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
about
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
description
clinical trial
@en
klinisch onderzoek
@nl
name
Multi-Center Phase II Study to ...... ctory Prostate Cancer Patients
@en
type
label
Multi-Center Phase II Study to ...... ctory Prostate Cancer Patients
@en
prefLabel
Multi-Center Phase II Study to ...... ctory Prostate Cancer Patients
@en
P17
P6153
P1476
A Multi-Center Phase II Study ...... ctory Prostate Cancer Patients
@en
P3098
NCT00636740
P4844
P580
2008-02-01T00:00:00Z
P582
2009-02-01T00:00:00Z